» Articles » PMID: 1486593

Ischaemic Preconditioning Limits Infarct Size in the Rat Heart

Overview
Journal Cardiovasc Res
Date 1992 Oct 1
PMID 1486593
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: One of the mechanisms by which ischaemic preconditioning is thought to protect against later prolonged ischaemia is via a reduction in ATP utilisation during ischaemia. The ATP "wastage" that occurs during ischaemia is thought to be due to mitochondrial ATPase activity, which may be prevented in ischaemic preconditioning by the binding of a specific inhibitor protein. As the rat is known to have less inhibitor protein than other species, this study was designed to determine whether the rat heart could be ischaemically preconditioned.

Methods: Rats were anaesthetised with pentobarbitone, the chest opened and the hearts ischaemically preconditioned with a 5 min occlusion of the left main coronary artery followed by 10 min reperfusion. The hearts were then subjected to a 45 min occlusion followed by 3 h reperfusion. Control hearts were treated identically but without ischaemic preconditioning. Infarct size was measured using triphenyl tetrazolium and expressed as a percentage of the region at risk, measured with fluorescent particles.

Results: Infarct size as a percent of the risk area in the ischaemically preconditioned group (n = 8) was 31.4(SEM 6.1)%, versus 61.0(4.8)% in control hearts (n = 8) (p < 0.005).

Conclusions: These results show that rat hearts can be ischaemically preconditioned and suggest that the protective mechanism involved in this phenomenon is not mediated through the endogenous inhibition of mitochondrial ATPase. An overall reduction in mitochondrial ATP "wastage" may not be the sole mechanism in the protection seen in ischaemic preconditioning.

Citing Articles

Initial Despair and Current Hope of Identifying a Clinically Useful Treatment of Myocardial Reperfusion Injury: Insights Derived from Studies of Platelet P2Y Antagonists and Interference with Inflammation and NLRP3 Assembly.

Cohen M, Downey J Int J Mol Sci. 2024; 25(10).

PMID: 38791515 PMC: 11122283. DOI: 10.3390/ijms25105477.


An overview of protective strategies against ischemia/reperfusion injury: The role of hyperbaric oxygen preconditioning.

Hentia C, Rizzato A, Camporesi E, Yang Z, Muntean D, Sandesc D Brain Behav. 2018; 8(5):e00959.

PMID: 29761012 PMC: 5943756. DOI: 10.1002/brb3.959.


Protein kinase C and cardiac dysfunction: a review.

Singh R, Cummings E, Pantos C, Singh J Heart Fail Rev. 2017; 22(6):843-859.

PMID: 28702857 PMC: 5635086. DOI: 10.1007/s10741-017-9634-3.


A Novel Category of Anti-Hypertensive Drugs for Treating Salt-Sensitive Hypertension on the Basis of a New Development Concept.

Katori M, Majima M Pharmaceuticals (Basel). 2016; 3(1):59-109.

PMID: 27713243 PMC: 3991021. DOI: 10.3390/ph3010059.


The challenge of translating ischemic conditioning from animal models to humans: the role of comorbidities.

McCafferty K, Forbes S, Thiemermann C, Yaqoob M Dis Model Mech. 2014; 7(12):1321-33.

PMID: 25481012 PMC: 4257001. DOI: 10.1242/dmm.016741.